Log in

NYSEAMERICAN:SYNSynthetic Biologics Competitors & Alternatives

$0.59
-0.01 (-1.31 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.56
Now: $0.59
$0.60
50-Day Range N/A
52-Week Range
$0.25
Now: $0.59
$0.75
Volume356,706 shs
Average Volume436,834 shs
Market Capitalization$11.41 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Synthetic Biologics (NYSEAMERICAN:SYN) Vs. ARMP, ARMP, HEPA, CANF, BPMX, and CANF

Should you be buying SYN stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Synthetic Biologics, including AmpliPhi Biosciences (ARMP), Armata Pharmaceuticals (ARMP), ContraVir Pharmaceuticals (HEPA), Can-Fite Biopharma (CANF), Biopharmx (BPMX), and CAN-FITE BIOPHA/S (CANF).

Synthetic Biologics (NYSEAMERICAN:SYN) and AmpliPhi Biosciences (NASDAQ:ARMP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.

Profitability

This table compares Synthetic Biologics and AmpliPhi Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Synthetic BiologicsN/AN/AN/A
AmpliPhi BiosciencesN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Synthetic Biologics and AmpliPhi Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Synthetic Biologics00203.00
AmpliPhi Biosciences00103.00

Synthetic Biologics presently has a consensus price target of $1.3750, indicating a potential upside of 134.24%. Given Synthetic Biologics' higher probable upside, analysts clearly believe Synthetic Biologics is more favorable than AmpliPhi Biosciences.

Valuation & Earnings

This table compares Synthetic Biologics and AmpliPhi Biosciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Synthetic BiologicsN/AN/AN/AN/AN/A
AmpliPhi BiosciencesN/AN/AN/AN/AN/A

Summary

Synthetic Biologics beats AmpliPhi Biosciences on 2 of the 2 factors compared between the two stocks.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) and Synthetic Biologics (NYSEAMERICAN:SYN) are both small-cap health technology companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.

Earnings and Valuation

This table compares Armata Pharmaceuticals and Synthetic Biologics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Armata PharmaceuticalsN/AN/AN/AN/AN/A
Synthetic BiologicsN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations for Armata Pharmaceuticals and Synthetic Biologics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Armata Pharmaceuticals00303.00
Synthetic Biologics00203.00

Armata Pharmaceuticals currently has a consensus target price of $7.3333, indicating a potential upside of 100.91%. Synthetic Biologics has a consensus target price of $1.3750, indicating a potential upside of 134.24%. Given Synthetic Biologics' higher probable upside, analysts clearly believe Synthetic Biologics is more favorable than Armata Pharmaceuticals.

Profitability

This table compares Armata Pharmaceuticals and Synthetic Biologics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Armata PharmaceuticalsN/AN/AN/A
Synthetic BiologicsN/AN/AN/A

Synthetic Biologics (NYSEAMERICAN:SYN) and ContraVir Pharmaceuticals (NYSE:HEPA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.

Analyst Recommendations

This is a summary of recent ratings for Synthetic Biologics and ContraVir Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Synthetic Biologics00203.00
ContraVir Pharmaceuticals00103.00

Synthetic Biologics presently has a consensus price target of $1.3750, indicating a potential upside of 134.24%. Given Synthetic Biologics' higher probable upside, research analysts clearly believe Synthetic Biologics is more favorable than ContraVir Pharmaceuticals.

Profitability

This table compares Synthetic Biologics and ContraVir Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Synthetic BiologicsN/AN/AN/A
ContraVir PharmaceuticalsN/AN/AN/A

Earnings & Valuation

This table compares Synthetic Biologics and ContraVir Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Synthetic BiologicsN/AN/AN/AN/AN/A
ContraVir PharmaceuticalsN/AN/AN/AN/AN/A

Summary

Synthetic Biologics beats ContraVir Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Can-Fite Biopharma (NASDAQ:CANF) and Synthetic Biologics (NYSEAMERICAN:SYN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Can-Fite Biopharma and Synthetic Biologics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Can-Fite Biopharma0000N/A
Synthetic Biologics00203.00

Synthetic Biologics has a consensus price target of $1.3750, indicating a potential upside of 134.24%. Given Synthetic Biologics' higher possible upside, analysts plainly believe Synthetic Biologics is more favorable than Can-Fite Biopharma.

Profitability

This table compares Can-Fite Biopharma and Synthetic Biologics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Can-Fite BiopharmaN/AN/AN/A
Synthetic BiologicsN/AN/AN/A

Earnings and Valuation

This table compares Can-Fite Biopharma and Synthetic Biologics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Can-Fite BiopharmaN/AN/AN/AN/AN/A
Synthetic BiologicsN/AN/AN/AN/AN/A

Summary

Synthetic Biologics beats Can-Fite Biopharma on 2 of the 2 factors compared between the two stocks.

Biopharmx (NYSEAMERICAN:BPMX) and Synthetic Biologics (NYSEAMERICAN:SYN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends.

Earnings & Valuation

This table compares Biopharmx and Synthetic Biologics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiopharmxN/AN/AN/AN/AN/A
Synthetic BiologicsN/AN/AN/AN/AN/A

Profitability

This table compares Biopharmx and Synthetic Biologics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BiopharmxN/AN/AN/A
Synthetic BiologicsN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Biopharmx and Synthetic Biologics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biopharmx01002.00
Synthetic Biologics00203.00

Biopharmx presently has a consensus target price of $12.00, indicating a potential upside of 548.65%. Synthetic Biologics has a consensus target price of $1.3750, indicating a potential upside of 134.24%. Given Biopharmx's higher possible upside, research analysts clearly believe Biopharmx is more favorable than Synthetic Biologics.

Summary

Synthetic Biologics beats Biopharmx on 2 of the 3 factors compared between the two stocks.

Synthetic Biologics (NYSEAMERICAN:SYN) and CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

Earnings & Valuation

This table compares Synthetic Biologics and CAN-FITE BIOPHA/S's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Synthetic BiologicsN/AN/AN/AN/AN/A
CAN-FITE BIOPHA/SN/AN/AN/AN/AN/A

Profitability

This table compares Synthetic Biologics and CAN-FITE BIOPHA/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Synthetic BiologicsN/AN/AN/A
CAN-FITE BIOPHA/SN/AN/AN/A

Analyst Ratings

This is a summary of current ratings for Synthetic Biologics and CAN-FITE BIOPHA/S, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Synthetic Biologics00203.00
CAN-FITE BIOPHA/S00103.00

Synthetic Biologics currently has a consensus price target of $1.3750, suggesting a potential upside of 134.24%. CAN-FITE BIOPHA/S has a consensus price target of $5.00, suggesting a potential upside of 132.56%. Given Synthetic Biologics' higher possible upside, equities research analysts plainly believe Synthetic Biologics is more favorable than CAN-FITE BIOPHA/S.

Institutional & Insider Ownership

5.1% of CAN-FITE BIOPHA/S shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Synthetic Biologics beats CAN-FITE BIOPHA/S on 2 of the 3 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ARMP
AmpliPhi Biosciences
0.6$3.65-1.6%$41.09 millionN/A0.00Upcoming Earnings
ARMP
Armata Pharmaceuticals
1.3$3.65-1.6%$40.65 millionN/A0.00Upcoming Earnings
HEPA
ContraVir Pharmaceuticals
0.6$4.39-0.5%$39.76 millionN/A0.00Upcoming Earnings
Heavy News Reporting
CANF
Can-Fite Biopharma
0.5$2.15-2.3%$38.38 millionN/A0.00
Biopharmx logo
BPMX
Biopharmx
1.2$1.85-1.1%$33.81 millionN/A0.00
CAN-FITE BIOPHA/S logo
CANF
CAN-FITE BIOPHA/S
1.3$2.15-2.3%$33.71 millionN/A0.00
NovaBay Pharmaceuticals logo
NBY
NovaBay Pharmaceuticals
0.8$1.14-16.7%$32.41 millionN/A0.00Earnings Announcement
Insider Selling
Heavy News Reporting
SLS
Galena Biopharma
0.5$3.42-2.6%$23.88 millionN/A0.00Upcoming Earnings
INTI
Inhibitor Therapeutics
0.3$0.06-0.0%$22.42 millionN/A0.00
BCDA
Biocardia
0.6N/AN/A$18.21 millionN/A0.00Heavy News Reporting
HEB
Hemispherx BioPharma
1.1$2.99-2.3%$7.30 millionN/A0.00High Trading Volume
Heavy News Reporting
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.5$0.03-0.3%$1.22 millionN/A0.00Heavy News Reporting
SOAN
AngioSoma
0.5$0.00-7.7%$671,000.00N/A0.00
Asterias Biotherapeutics logo
AST
Asterias Biotherapeutics
0.5$0.00-0.0%$111,000.00N/A0.00
ATTBF
Abattis Bioceuticals
0.4$0.01-4.0%$0.00N/A0.00Heavy News Reporting
LBTSF
Almirall
0.5$11.30-0.0%$0.00N/A0.00
CBDC
Apotheca Biosciences
0.4$0.03-0.0%$0.00N/A0.00
ARNI
Arno Therapeutics
0.5$0.00-8.7%$0.00N/A0.00
AXIM
Axim Biotechnologies
0.4$0.82-1.2%$0.00N/A0.00
BXRXV
Baudax Bio
0.5$3.98-0.0%$0.00N/A0.00High Trading Volume
Heavy News Reporting
BRRGF
BerGenBio ASA
0.7$3.75-3.2%$0.00N/A0.00Heavy News Reporting
CNBX
Cannabics Pharmaceuticals
0.4$0.20-4.4%$0.00N/A0.00
ORHOF
CannaRoyalty
0.7$4.05-0.0%$0.00N/A0.00
CGYG
China Longyi Group Int'l
0.4$0.00-0.0%$0.00N/A0.00
CELZ
Creative Medical Technology
0.5$0.00-12.5%$0.00N/A0.00High Trading Volume
CYCCP
Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs
0.5$5.63-0.0%$0.00N/A0.00
diaDexus logo
DDXS
diaDexus
0.5N/AN/A$0.00N/A0.00High Trading Volume
ETBI
Eastgate Biotech
0.5$0.00-0.0%$0.00N/A0.00
EMMBF
Emblem
0.6$1.40-0.0%$0.00N/A0.00Heavy News Reporting
GBLX
GB Sciences
0.5$0.03-7.2%$0.00N/A0.00Upcoming Earnings
GNFTF
Genfit
0.5$4.90-0.0%$0.00N/A0.00
GMXAY
GENMAB A/S/S
0.5$36.52-0.5%$0.00N/A0.00High Trading Volume
IDRSF
Idorsia
0.6$28.35-0.0%$0.00N/A0.00
IPATF
Immunoprecise Antibodies
0.5$1.09-1.4%$0.00N/A0.00
IMLFF
InMed Pharmaceuticals
0.9$5.26-8.4%$0.00N/A0.00
IPIX
Innovation Pharmaceuticals
0.5$0.25-2.8%$0.00N/A0.00
KALTF
Kalytera Therapeutics
0.6$0.00-0.0%$0.00N/A0.00Heavy News Reporting
LIXT
Lixte Biotechnology
0.5$1.19-0.0%$0.00N/A0.00
MDCN
Medican Enterprises
0.5N/AN/A$0.00N/A0.00
MMEDF
Medicine Mind
0.6$0.35-2.4%$0.00N/A0.00Heavy News Reporting
MEOBF
Mesoblast
0.5$2.70-0.0%$0.00N/A0.00
MLLCF
Molecular Partners
0.8$19.50-1.0%$0.00N/A0.00Heavy News Reporting
NVZMF
Novozymes A/S
0.4$59.86-1.1%$0.00N/A0.00
BPSR
Organicell Regenerative Medicine
0.5$0.15-16.3%$0.00N/A0.00High Trading Volume
Heavy News Reporting
PTEO
Proteo
0.5$0.09-0.0%$0.00N/A0.00
PKTX
ProtoKinetix
1.1$0.09-4.7%$0.00N/A0.00
SGBI
Sangui Biotech International
0.7$0.01-0.0%$0.00N/A0.00
SLS International logo
SLS
SLS International
1.4N/AN/A$0.00N/A0.00High Trading Volume
SOLCF
SOL Global Investments
0.3$0.30-4.3%$0.00N/A0.00
SOLTF
Sosei Group
0.5$14.45-0.0%$0.00N/A0.00
This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.